Yearly Archives: 2020


Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society…

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules (ADS-5102) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2020 Virtual Congress, September 12-16, 2020.

Original post:
Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society...

Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational…

-- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 --SAN DIEGO and CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from  PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment with investigational gene therapy, NBIb-1817 (VY-AADC), showed sustained improvement in motor function including greater “On” time without troublesome dyskinesia, reduction in Unified Parkinson’s Disease Rating Scale (UPDRS) Part III scores, and reduction in the amount of medications in patients with Parkinson’s disease. In the PD-1101 study, NBIb-1817 reduced average “Off” time by up to -1.91 hours and improved average “On” time without troublesome dyskinesia by up to +2.23 hours in patients with advanced Parkinson’s disease after three years across three cohorts. In addition, 14 out of 15 patients treated with NBIb-1817 continued to show an improvement in disease staging after three years, as assessed by the modified Hoehn & Yahr scale. These new data, along with two-year data from another open-label Phase Ib trial, PD-1102, were presented today at the MDS Virtual Congress 2020, September 12–16, 2020 (www.mdscongress.org/Congress/Registration.htm).

Read more:
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational...

Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States

NEW YORK, NY, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that the U.S. Food and Drug Administration (FDA) has added the  TODOS 2019-nCoV RT-qPCR Detection Kit to its Notified List under the Emergency Use Authorization program. Todos is required to submit an Emergency Use Authorization application to the FDA within 15 days of submission of the notification.

Read more:
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States

Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) --  Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming H.C. Wainwright Global Healthcare Conference held on September 14/15, 2020, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG).

Read more:
Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference

NK Cell Therapy and Stem Cell Therapy Market Research, Clinical Study and Business Guidelines till 2026 | Chipscreen Biosciences Innate Pharma SA …

Global NK Cell Therapy and Stem Cell Therapy Market Research Report presents the overview and in depth study of worldwide NK Cell Therapy and Stem Cell Therapy Market for achieving throughout understanding and business intelligence of the market with the Financial & Industrial Analysis of key players, companies, region, types, applications and its future scope in the industry till 2027.

The NK Cell Therapy and Stem Cell Therapy market revenue was valued at xx.xx Million USD in 2020 and it is expected to reach xx.xx Million USD in 2027, with a CAGR of x.x% during 2020-2027. Based on the NK Cell Therapy and Stem Cell Therapy industrial chain, this report mainly elaborates the definition, types, applications and major players of NK Cell Therapy and Stem Cell Therapy market in details.

Get Sample Brochure(PDF) of NK Cell Therapy and Stem Cell Therapy market at: https://decisionmarketreports.com/request-sample/1374947

Deep analysis about market status (2014-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2024), regional industrial layout characteristics and macroeconomic policies, industrial policy has also be included.

From raw materials to downstream buyers of this industry will be analyzed scientifically, the feature of product circulation and sales channel will be presented as well. In a word, this report will help you to establish a panorama of industrial development and characteristics of the NK Cell Therapy and Stem Cell Therapy market.

The NK Cell Therapy and Stem Cell Therapy market can be split based on product types, major applications, and important regions.

Major Players in NK Cell Therapy and Stem Cell Therapy market are: Chipscreen Biosciences Innate Pharma SA Osiris Therapeutics Chiesi Pharmaceuticals Molmed JCR Pharmaceutical Altor BioScience Corporation Affimed NV Takeda Pharmaceutical Pharmicell Medi-post NuVasive Anterogen

Most important types of NK Cell Therapy and Stem Cell Therapy products covered in this report are: NK Cell Therapy Stem Cell Therapy

Most widely used downstream fields of NK Cell Therapy and Stem Cell Therapy market covered in this report are: Hospital & clinics Regenerative medicine centers Diagnostic centers Research institutes Others

Major Regions that plays a vital role in NK Cell Therapy and Stem Cell Therapy market are: North America Europe China Japan Middle East & Africa India South America Others

Request to Purchase the Full NK Cell Therapy and Stem Cell Therapy market report at: https://decisionmarketreports.com/market-reports/1374947/global-nk-cell-therapy-and-stem-cell-therapy-market/single-user/checkout

There are 13 Chapters to thoroughly display the NK Cell Therapy and Stem Cell Therapy market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

Chapter 1: NK Cell Therapy and Stem Cell Therapy Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: NK Cell Therapy and Stem Cell Therapy Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market

Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of NK Cell Therapy and Stem Cell Therapy.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of NK Cell Therapy and Stem Cell Therapy.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of NK Cell Therapy and Stem Cell Therapy by Regions (2014-2020).

Chapter 6: NK Cell Therapy and Stem Cell Therapy Production, Consumption, Export and Import by Regions (2014-2020).

Chapter 7: NK Cell Therapy and Stem Cell Therapy Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of NK Cell Therapy and Stem Cell Therapy.

Chapter 9: NK Cell Therapy and Stem Cell Therapy Market Analysis and Forecast by Type and Application (2020-2024).

Chapter 10: Market Analysis and Forecast by Regions (2020-2024).

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

About Us Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

Contact Us Gasper James 304, S Jones Blvd, Las Vegas, NV 89107, USA US Toll Free +18666051052 Email: [emailprotected] Web: http://decisionmarketreports.com/

Original post:
NK Cell Therapy and Stem Cell Therapy Market Research, Clinical Study and Business Guidelines till 2026 | Chipscreen Biosciences Innate Pharma SA ...